ReviewBiomolecules & biomedicine2026
Review in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide. Atherosclerosis, the primary pathological mechanism underlying CVDs, culminates in endothelial dysfunction (ED). Reversible ED, characterized by impaired vascular relaxation and increased inflammation, represents a critical therapeutic target. Moringa oleifera (M. oleifera), often referred to as the "miracle tree," is garnering significant interest due to its broad spectrum of medicinal properties, including antihypertensive and endothelial-protective activities. Rich in bioactive compounds such as flavonoids, polyphenols, and vitamins, this plant exhibits diverse pharmacological activities.This review aims to explore the role of M. oleifera in hypertension management and the improvement of endothelial function. Clinical evidence primarily supports the blood pressure-lowering effects of M. oleifera. Preclinical studies, however, suggest additional mechanisms, including enhanced nitric oxide (NO) bioavailability, angiotensin-converting enzyme (ACE) inhibition, potent antioxidant activity, diuretic effects, and direct endothelial protective actions. Furthermore, preclinical findings elucidate that its vasodilatory and diuretic effects may involve NO-mediated pathways, hydrogen sulfide (H₂S) signaling, and endothelium-derived hyperpolarizing factor (EDHF)-dependent mechanisms, thereby highlighting its potential therapeutic value in vascular health. Its antioxidant capacity may also confer protection against the oxidative and nitrosative stress commonly associated with hypertension- and diabetes-induced endothelial dysfunction. While promising, the majority of current evidence is derived from animal models and small-scale clinical studies. Therefore, further well-designed, large-scale human studies are imperative to definitively establish the efficacy and safety of M. oleifera as a natural therapeutic agent for cardiovascular health. This review underscores the critical need for additional research to fully clarify the therapeutic potential of M. oleifera in the prevention and management of CVDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.